(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

What Is The Projected Market Size & Growth Rate Of The Hyperphosphatemia Treatment Market?
In recent times, the hyperphosphatemia treatment market has seen a substantial increase in its size. The market is forecasted to expand from $4.56 billion in 2024 to about $5.08 billion in 2025, with a compound annual growth rate (CAGR) of around 11.4%. This significant growth in the historic period can be linked to the rising incidents of chronic kidney disease (CKD), an increase in the elderly population, a high rate of diabetes and hypertension, the expansion of the dialysis patient population, and advancements in medical research and hyperphosphatemia diagnosis.

In the coming years, the market size for hyperphosphatemia treatment is predicted to experience quick expansion, increasing to ""$8.38 billion in 2029 with a compound annual growth rate (CAGR) of 13.3%. The projected growth in this period is attributed to factors such as an increase in diseases related to lifestyle which cause hyperphosphatemia, a steady rise in older demographics, enhanced understanding and diagnosis of hyperphosphatemia, and expansion of emerging markets with a significant disease burden. Also, there is an increased prescription trend of calcium-based phosphate binders in developing nations. The forecast period is set to witness trends such as advancements in the technology used for hyperphosphatemia treatment, integration of remote patient monitoring and telehealth, collaborations and partnerships aimed at research and development, focus on patient education and lifestyle management in dealing with hyperphosphatemia, and the development of innovative phosphate binders and treatments.

Download a free sample of the hyperphosphatemia treatment market report:

What Is The Crucial Factor Driving The Global Hyperphosphatemia Treatment Market?
The growth of the hyperphosphatemia treatment market is being propelled by a rise in chronic illnesses among patients. These non-communicable chronic ailments necessitate long-term healthcare. Conditions like cardiovascular diseases, chronic kidney disorder, chronic respiratory diseases, hyperparathyroidism, diabetes, and cancer form a significant chunk of these chronic diseases. For example, as per data from the World Health Organization, a specialized agency of the United Nations based in Switzerland, in September 2023, 41 million deaths globally were recorded, constituting 74% of the total deaths caused by non-communicable diseases or chronic diseases. Moreover, SingleCare Services LLC, an American healthcare savings platform, reported in February 2023 that kidney diseases were becoming more common, leading to the death of about 1 million people each year due to untreated kidney failure. An increase in hyperphosphatemia in patients suffering from end-stage renal disease (ESRD) has subsequently led to a surge in the demand for hyperphosphatemia treatment or drugs.

Who Are The Emerging Players In The Hyperphosphatemia Treatment Market?
Major players in the Hyperphosphatemia Treatment include:
. Sanofi SA
. Akebia Therapeutics Inc.
. Ardelyx Inc.
. Astellas Pharma Inc.
. Fresenius Medical Care AG & Co. KGaA
. Lupin Limited
. Sun Pharmaceutical Industries Ltd.
. Takeda Pharmaceutical Company Limited
. Ultragenyx Pharmaceutical Inc.
. Unicycive Therapeutics Inc.

What Are The Key Trends Shaping The Hyperphosphatemia Treatment Industry?
The escalating efforts in research and development stand as a significant trend in the hyperphosphatemia treatment market. Companies operating in this market are dedicating their resources towards R&D to devise innovative treatment methods for kidney-related diseases and associated chronic issues. In particular, Eurostat, a European government agency, reported in April 2024 that the Ile-de-France region in France had the highest number of core human resources in science and technology in Europe, a total of 2.4 million. Following France, the Comunidad de Madrid region in Spain held the second-highest count boasting 1.2 million.

What Segments Are Covered In The Hyperphosphatemia Treatment Market Report?
The hyperphosphatemia treatment market covered in this report is segmented –
1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products
2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores

Subsegments:
1) By Sevelamer: Sevelamer Hydrochloride, Sevelamer Carbonate
2) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
3) By Iron-Based Phosphate Binders: Ferric Citrate, Ferric Sulfate
4) By Lanthanum Carbonate: Lanthanum Carbonate Hydrate
5) By Other Products: Magnesium-Based Phosphate Binders, Novel Phosphate Binders

View the full hyperphosphatemia treatment market report:

Which Region Is Projected To Hold The Largest Market Share In The Global Hyperphosphatemia Treatment Market?
In 2024, North America led the hyperphosphatemia treatment market, with Asia-Pacific projected to experience the most rapid growth in subsequent years. The report spans several regions, specifically Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Hyperphosphatemia Treatment Market 2025, By The Business Research Company

Gastrointestinal Bleeding Treatment Devices Global Market Report 2025
/report/gastrointestinal-bleeding-treatment-devices-global-market-report

Gastrointestinal Devices Global Market Report 2025
/report/gastrointestinal-devices-global-market-report

Medical Equipment Maintenance Global Market Report 2025
/report/medical-equipment-maintenance-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn: "

MENAFN20112025003118003196ID1110377239